Rep. April McClain Delaney Sells Off STERIS plc (NYSE:STE) Stock

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on August 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in STERIS stock on July 27th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Life Time Group (NYSE:LTH) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Liberty Media Corporation – Liberty Formula One Series C (NASDAQ:FWONK) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of C.H. Robinson Worldwide (NASDAQ:CHRW) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Somnigroup International (NYSE:SGI) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Entegris (NASDAQ:ENTG) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Life Time Group (NYSE:LTH) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Service Corporation International (NYSE:SCI) on 7/30/2026.

STERIS Trading Up 0.2%

NYSE:STE opened at $233.17 on Wednesday. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $22.72 billion, a price-to-earnings ratio of 29.40 and a beta of 0.91. The firm has a fifty day simple moving average of $213.64 and a two-hundred day simple moving average of $225.91. STERIS plc has a 12 month low of $195.14 and a 12 month high of $269.44.

STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. STERIS’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Analysts expect that STERIS plc will post 11.17 EPS for the current fiscal year.

STERIS Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Friday, September 4th will be paid a dividend of $0.69 per share. This is a boost from STERIS’s previous quarterly dividend of $0.63. This represents a $2.76 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Friday, September 4th. STERIS’s payout ratio is currently 31.78%.

Analysts Set New Price Targets

STE has been the topic of several recent research reports. Wall Street Zen lowered STERIS from a “buy” rating to a “hold” rating in a report on Saturday. Piper Sandler reaffirmed an “overweight” rating and set a $270.00 target price on shares of STERIS in a research report on Thursday, May 21st. KeyCorp cut their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings lowered shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Finally, UBS Group started coverage on shares of STERIS in a research note on Tuesday, July 28th. They issued a “buy” rating and a $275.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, STERIS currently has an average rating of “Moderate Buy” and a consensus target price of $277.25.

Institutional Trading of STERIS

Institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp boosted its holdings in STERIS by 46.1% during the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after purchasing an additional 349 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in STERIS by 32.3% during the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after acquiring an additional 59,264 shares during the period. Empowered Funds LLC boosted its position in STERIS by 16.1% in the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after purchasing an additional 319 shares during the last quarter. Woodline Partners LP grew its stake in STERIS by 40.0% in the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after purchasing an additional 2,372 shares during the period. Finally, Jane Street Group LLC increased its position in shares of STERIS by 38.9% during the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after purchasing an additional 5,803 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling

In other STERIS news, Director Richard C. Breeden sold 1,481 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total value of $310,284.31. Following the transaction, the director directly owned 38,964 shares in the company, valued at $8,163,347.64. The trade was a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP John Adam Zangerle sold 1,419 shares of STERIS stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the completion of the sale, the vice president directly owned 35,259 shares in the company, valued at $7,379,003.52. This trade represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 7,328 shares of company stock valued at $1,554,051. 1.12% of the stock is owned by insiders.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.